使用经抗 tenascin C CAR 和可分泌 EGFRxCD3 双特异性抗体修饰的细胞因子诱导杀伤细胞对实体瘤进行双重靶向
Dual targeting of solid tumors using cytokine-induced killer cells modified with a CAR anti-tenascin C and a secretable EGFRxCD3 bispecific antibody.
55.5分
★★★☆☆
站内排序·非疗效
FRONTIER PAPERS
Dual targeting of solid tumors using cytokine-induced killer cells modified with a CAR anti-tenascin C and a secretable EGFRxCD3 bispecific antibody.
The peptide-based bispecific CAR T cells target EGFR and tumor stroma for effective cancer therapy.
我们的研究结果表明,基于肽的双特异性 CAR-T 细胞因其对肿瘤及肿瘤微环境的出色靶向能力,在实体瘤治疗中展现出巨大潜力。
共 2 条
MEMBER ACCOUNT
登录成功会直接打开下一页。